Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.
Ter Haar ELM, Thomas SE, van den Reek JMPA, Otero ME, Njoo MD, Ossenkoppele PM, Kop EN, Dodemont SRP, Körver JEM, Kuijpers ALA, Lindhout RJ, Tupker RA, Mommers JM, Berends MAM, Koetsier MIA, de Bruin-Weller MS, Visch MB, Arnold WP, van Lümig PPM, Kleinpenning MM, Lubeek SFK, de Jong EMGJ. Ter Haar ELM, et al. Among authors: koetsier mia. Drugs Aging. 2022 Sep;39(9):715-727. doi: 10.1007/s40266-022-00961-y. Epub 2022 Jul 21. Drugs Aging. 2022. PMID: 35859228 Free PMC article.
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
Atalay S, van den Reek JMPA, den Broeder AA, van Vugt LJ, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MI, Berends MA, van de Kerkhof PCM, Groenewoud HMM, Kievit W, de Jong EMGJ. Atalay S, et al. JAMA Dermatol. 2020 Apr 1;156(4):393-400. doi: 10.1001/jamadermatol.2019.4897. JAMA Dermatol. 2020. PMID: 32049319 Free PMC article. Clinical Trial.
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial.
Atalay S, Berends SE, Groenewoud HMM, Mathot RAA, Njoo DM, Mommers JM, Ossenkoppele PM, Koetsier MIA, Berends MA, de Vries A, van de Kerkhof PCM, den Broeder AA, de Jong EMGJ, van den Reek JMPA. Atalay S, et al. Among authors: koetsier mia. J Dermatolog Treat. 2022 Aug;33(5):2680-2684. doi: 10.1080/09546634.2022.2043546. Epub 2022 Feb 23. J Dermatolog Treat. 2022. PMID: 35193441 Clinical Trial.
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Van Muijen ME, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD, Dodemont SRP, Kop EN, Berends MAM, Koetsier MIA, Mommers JM, Körver JEM, Tupker RA, De Bruin-Weller MS, Weppner-Parren LJMT, Peters B, Kleinpenning MM, Kuijpers ALA, Arnold WP, Van Lümig PPM, Van den Reek JMPA, De Jong EMGJ. Van Muijen ME, et al. Among authors: koetsier mia. Acta Derm Venereol. 2022 May 16;102:adv00712. doi: 10.2340/actadv.v102.206. Acta Derm Venereol. 2022. PMID: 35356990 Free PMC article.
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.
van den Reek JM, Zweegers J, Kievit W, Otero ME, van Lümig PP, Driessen RJ, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, van de Kerkhof PC, Seyger MM, de Jong EM. van den Reek JM, et al. Br J Dermatol. 2014 Nov;171(5):1189-96. doi: 10.1111/bjd.13087. Epub 2014 Oct 3. Br J Dermatol. 2014. PMID: 24807471
Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE.
Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, Kievit W, de Jong EM. Zweegers J, et al. Br J Dermatol. 2014 Nov;171(5):1091-8. doi: 10.1111/bjd.13137. Epub 2014 Oct 20. Br J Dermatol. 2014. PMID: 24861358
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Ossenkoppele PM, Njoo MD, Mommers JM, van Lümig PP, Driessen RJ, Kievit W, de Jong EM. Zweegers J, et al. Br J Dermatol. 2016 Aug;175(2):340-7. doi: 10.1111/bjd.14552. Epub 2016 Jun 25. Br J Dermatol. 2016. PMID: 26989852
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Zweegers J, Roosenboom B, van de Kerkhof PC, van den Reek JM, Otero ME, Atalay S, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Bijen M, Njoo MD, Mommers JM, van Lümig PP, Driessen RJ, Kievit W, de Jong EM. Zweegers J, et al. Br J Dermatol. 2017 Mar;176(3):786-793. doi: 10.1111/bjd.14888. Epub 2016 Oct 7. Br J Dermatol. 2017. PMID: 27454758
Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J, Groenewoud JMM, van den Reek JMPA, Otero ME, van de Kerkhof PCM, Driessen RJB, van Lümig PPM, Njoo MD, Ossenkoppele PM, Mommers JM, Koetsier MIA, Arnold WP, Andriessen MPM, Kuijpers ALA, Berends MAM, Kievit W, de Jong EMGJ. Zweegers J, et al. Among authors: koetsier mia. Br J Dermatol. 2017 Apr;176(4):1001-1009. doi: 10.1111/bjd.15023. Epub 2017 Mar 10. Br J Dermatol. 2017. PMID: 27579864
17 results